Downregulation of miR-129 in peripheral blood mononuclear cells is a diagnostic and prognostic biomarker in prostate cancer
- Resource Type
- Authors
- Xu, Song; Yi, Xiao-Ming; Zhou, Wen-Quan; Cheng, Wen; Ge, Jing-Ping; Zhang, Zheng-Yu
- Source
- Subject
- Adult
Male
Down-Regulation
Kaplan-Meier Estimate
Transfection
Disease-Free Survival
Predictive Value of Tests
Risk Factors
Cell Line, Tumor
Biomarkers, Tumor
Humans
Aged
Cell Proliferation
Neoplasm Staging
Proportional Hazards Models
Chi-Square Distribution
Reverse Transcriptase Polymerase Chain Reaction
Prostatic Neoplasms
Middle Aged
Gene Expression Regulation, Neoplastic
MicroRNAs
ROC Curve
Area Under Curve
Case-Control Studies
Multivariate Analysis
Leukocytes, Mononuclear
Original Article
Neoplasm Grading
- Language
- English
Objective: The present study was designed to explore the clinical values of microRNA-129 (miR-129) expression in peripheral blood mononuclear cells for prostate cancer patients and the role of miR-129 in the proliferation of prostate cancer. Methods: The peripheral blood mononuclear cells were isolated form blood simple from 98 patients confirmed with prostate cancer and 56 matched healthy volunteers. Reverse transcription quantitative real-time polymerase chain reaction (qRT-PCR) was employed to determine the expression level of miR-129 in peripheral blood mononuclear cells. Cox proportional hazards regression models and Kaplan-Meier analysis were used to evaluate the association of miR-129 expression with clinical and pathological characteristics of prostate cancer patients. The effect of miR-129 on the proliferation of prostate cancer cells in vitro was also determined. Results: Reverse transcription quantitative real-time polymerase chain reaction (qRT-PCR) results showed that the expression of miR-129 was dramatically down-regulated in peripheral blood mononuclear cells for prostate cancer patients in comparison with healthy controls (P